NCT01621568 2024-09-24
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
6 trialsNCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02364076 2019-12-13
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Georgetown University
Phase 2 Unknown
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT01100944 2017-08-10
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02233842 2016-09-12
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
National Institutes of Health Clinical Center (CC)
Completed